GLP-3 (Retatrutide) Pen 10 mg

10mg199,00 € incl. VAT

GLP-3 (Retatrutide) Pen 10 mg: pre-filled pen with retatrutide (triple GIP/GLP-1/glucagon receptor agonist) as a ready-to-use solution, 10 mg in a 2 mL cartridge (5 mg/mL). No reconstitution: the dial sets a fixed volume per click. The substance is independently tested by HPLC and the Certificate of Analysis is published on this page. For laboratory research use only.

Pre-order

Shipping from 11,93 € · Free EU shipping over 200 €

📋 View the Certificate of Analysis information

SKU: GLP3-10MG-PEN-KIT Category:

Product specifications

Quantity10mg
Unit1 pre-filled pen
Purity data99.6% (batch XD-RT10-PO06)
FormatPre-mixed pen (solution in cartridge)
Volume2 mL solution
Concentration5 mg/mL
Storage2–8 °C, protected from light
Source lotXD-RT10-PO06, tested by Liquilabs

Description

Research use only. Sold for laboratory research. Not a medicine, and not for human or veterinary use.

Pre-order

This pen is being prepared for its first production run. Orders placed now are reserved and ship as soon as stock arrives; you will get an email with tracking the day it leaves.

What is retatrutide?

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide that activates three receptors at once: GIP, GLP-1 and glucagon. This is why it is called a triple agonist, or "GLP-3". GLP-1 and GIP activity act on appetite, satiety and insulin secretion; the glucagon component adds an effect on energy expenditure and fat breakdown in the liver. It is an investigational compound in phase 3 trials and is not approved as a medicine anywhere.

What the research shows

  • Body weight. In the phase 2 obesity trial (Jastreboff et al., NEJM 2023; 338 adults, 48 weeks), mean weight change was −24.2% at 12 mg weekly, against −2.1% with placebo. At 24 weeks the 12 mg group was already at −17.5%.
  • Phase 3. Topline results from the first phase 3 trial (TRIUMPH-4, announced in December 2025) reported mean weight loss of 28.7% at 68 weeks on 12 mg, against 2.1% with placebo, in adults with obesity and knee osteoarthritis. Full results have not yet been published in a journal.
  • Blood glucose. In adults with type 2 diabetes (Rosenstock et al., Lancet 2023), HbA1c fell by up to about 2.0 percentage points at 24 weeks.
  • Liver fat. In a substudy of participants with fatty liver (Sanyal et al., Nature Medicine 2024), liver fat fell by more than 80% at the two highest doses after 24 weeks.
  • Lipids and blood pressure. Triglycerides, LDL cholesterol and blood pressure improved alongside the weight change.

Side effects reported in studies

Mostly gastrointestinal and dose-related: nausea, diarrhoea, vomiting and constipation, more frequent during dose escalation and with a higher starting dose. A dose-dependent rise in heart rate was observed, peaking around week 24 and then declining.

Doses reported in published studies

The phase 2 trial tested 1, 4, 8 and 12 mg once weekly by subcutaneous injection. The higher-dose groups started at 2 mg or 4 mg and stepped up every 4 weeks; starting at 2 mg produced fewer gastrointestinal effects than starting at 4 mg. The phase 3 trials use weekly maintenance doses of up to 12 mg.

This section summarises the doses used in the published literature. It is not a recommendation.

About the pre-mixed pen format

A pre-mixed pen holds the peptide already reconstituted inside a sealed cartridge, so there is no vial to open, no solvent to measure and no transfer step. The solution stays in a closed system from filling to use, and the dial delivers the same volume on every click. Each pen is filled from a lot of lyophilised substance that has already been through independent testing; the lot number is shown on this page.

Supplied as one pre-filled pen, without other accessories.

Pen or vial?

PenVial
Form on arrivalSolution in a cartridge (dual-chamber: powder and solvent, mixed on activation)Lyophilised powder
ReconstitutionNot neededDone by the user with bacteriostatic water
MeasuringDial, fixed volume per clickSyringe, calculated per draw
Handling stepsOneSeveral
Price per mgHigherLower
Best forConvenience and repeatable volumesLowest cost and the longest unopened shelf life

Prefer the lyophilised vial? See GLP-3 (Retatrutide) 10mg.

Storage

Keep the pen refrigerated at 2–8 °C, in its box and away from light. Do not freeze. Do not use if the solution is cloudy, discoloured or contains particles. Short temperature excursions during shipping are expected and are covered by insulated packaging.

Quality and Certificate of Analysis

The substance in this pen comes from lot XD-RT10-PO06, tested by Liquilabs, an independent laboratory: 99.6% purity by HPLC, with identity confirmed and endotoxin and heavy metals tested on the same report. The report is published in our lab reports archive, and the lot number can be checked on the laboratory's own site. The certificate describes the lyophilised source lot; the finished solution in the pen has not been analysed separately.

Frequently asked questions

When will my pre-ordered GLP-3 (Retatrutide) Pen 10 mg ship?

As soon as the first production run arrives. You receive tracking by email on the day it leaves.

Does the GLP-3 (Retatrutide) Pen 10 mg need to stay cold?

Yes. Keep it at 2–8 °C. It ships in insulated packaging.

What does the Certificate of Analysis cover?

The lot of lyophilised substance the pen was filled from. The finished solution in the pen has not been analysed separately.

What is in the box?

One pre-filled pen. Needles and other accessories are not included at the moment.

Is it the same substance as the vial?

Yes. It is the same substance in a different format.

Batch test records

The substance in this pen comes from the lot below. The report describes the lyophilised source lot; the finished solution in the pen has not been analysed separately.

XD-RT10-PO06Current lot
Tested
October 1, 2026
Assay
Purity, Endotoxin, Heavy metals
Purity
99.6%